Search Results

Genialis, the RNA-biomarker company, announced a new partnership with the Pancreatic Cancer Action Network to expand the validation of the Genialis™ krasID biomarker in the pancreatic cancer histology.

FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

The Pancreatic Cancer Action Network, the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.

The Pancreatic Cancer Action Network, a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of four esteemed business leaders, Jay T. Backstrom, MD, MPH, Rich Hume, Eric Park and Mace Rothenberg, MD, to its national board of directors.

In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network announced Oncolytics Biotech, Inc. as the recipient of its second annual PanCAN Therapeutic Accelerator Award.

The Pancreatic Cancer Action Network proudly announces the addition of fourteen new members to its Scientific and Medical Advisory Board, as well as the elevation of current SMAB members Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center and Gregory Beatty, MD, PhD to the roles of Chair and Vice Chair, respectively.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.

START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials